Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System-Reference-Cited by-同舟云学术

Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System

Published:2023-03-06 Issue:3 Volume:37 Page:397-407
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Jourdain Hugo^ORCID,Hoisnard Léa^ORCID,Sbidian Emilie^ORCID,Zureik Mahmoud^ORCID

Funder

Agence Nationale de Sécurité du Médicament et des Produits de Santé

Caisse Nationale d'Assurance Maladie

Assistance Publique - Hôpitaux de Paris

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-023-00584-8.pdf

Reference46 articles.

1. Salles G, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–73. https://doi.org/10.1007/s12325-017-0612-x.

2. Tavakolpour S, et al. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol. 2019;38(11):2977–94. https://doi.org/10.1007/s10067-019-04699-8.

3. Hassan RI, Gaffo AL. Rituximab in ANCA-associated vasculitis. Curr Rheumatol Rep. 2017. https://doi.org/10.1007/s11926-017-0632-1.

4. Frampton JE. Rituximab: a review in pemphigus vulgaris. Am J Clin Dermatol. 2020;21(1):149–56. https://doi.org/10.1007/s40257-019-00497-9.

5. Levin AS, Otani IM, Lax T, Hochberg E, Banerji A. Reactions to rituximab in an outpatient infusion center: a 5-year review. J Allergy Clin Immunol Pract. 2017;5(1):107.e1-113.e1. https://doi.org/10.1016/j.jaip.2016.06.022.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System;RMD Open;2024-03

2. Rituximab biosimilar: no increased risk of hypersensitivity reactions;Reactions Weekly;2023-03-25